MAP
ESPR icon

Moody Aldrich Partners’s Esperion Therapeutics ESPR Stock Holding History

Moody Aldrich Partners’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-62,245
Closed -$1.62M – 189
2020
Q4 		$1.62M Sell
62,245
-38,854
-38% -$1.16M 0.26% 97
2020
Q3 		$3.76M Sell
101,099
-2
-0% -$79 0.79% 58
2020
Q2 		$5.19M Buy
101,101
+12,341
+14% +$516K 1.1% 35
2020
Q1 		$2.8M Sell
88,760
-35,471
-29% -$1.87M 0.84% 48
2019
Q4 		$7.41M Buy
+124,231
New +$5.59M 1.52% 12
2018
Q2 		– Sell
-22,478
Closed -$1.63M – 101
2018
Q1 		$1.63M Buy
22,478
+11,151
+98% +$819K 1.04% 51
2017
Q4 		$746K Buy
11,327
+2,347
+26% +$126K 0.6% 76
2017
Q3 		$450K Sell
8,980
-2,355
-21% -$114K 0.46% 81
2017
Q2 		$525K Buy
+11,335
New +$417K 0.65% 73

Other funds holding ESPR

WA
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

Moody Aldrich Partners's ESPR Position: Q1 2021 in Review

Moody Aldrich Partners sold out of Esperion Therapeutics (ESPR) in Q1 2021, closing a stake of 62,245 shares — an estimated $1.62M sold.

Moody Aldrich Partners first reported a position in ESPR in Q2 2017 and held it in 9 quarters. The position peaked at $7.41M in Q4 2019. 156 funds tracked by Wall St. Rank hold ESPR as of Q1 2021.

  • Moody Aldrich Partners reported no remaining Esperion Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Moody Aldrich Partners sold 62,245 Esperion Therapeutics shares in Q1 2021, an estimated $1.62M.
  • Moody Aldrich Partners first reported a position in Esperion Therapeutics in Q2 2017 and held it in 9 quarters.
  • Moody Aldrich Partners's Esperion Therapeutics position peaked at $7.41M in Q4 2019.
  • 156 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2021.

Based on Moody Aldrich Partners's 13F filing for Q1 2021, filed 10 May 2021.